FDA committee votes 12-0 for myeloma trial outcome measure
A unanimous vote by a committee of the U.S.
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
CAR T-cell therapy Carvykti OK’d as second-line RRMM treatment
The U.S. Food and Drug Administration (FDA) has approved…
Abecma OK’d in US to take earlier in treatments for multiple myeloma
The U.S. Food and Drug Administration (FDA) has expanded…
Steroid-free Venclexta combo shows promise in myeloma cells
Combining the cancer therapy Venclexta (venetoclax) with a molecule…
Abecma cleared in EU as earlier therapy for hard-to-treat myeloma
The European Commission has approved Bristol Myers Squibb…
CAR T-cell therapy recommended as earlier treatment line for RRMM
An advisory committee of the U.S. Food and Drug…
